TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Impedimed Limited ( (AU:IPD) ) is now available.
ImpediMed Limited has announced that additional U.S. insurers have initiated coverage for the use of bioimpedance spectroscopy (BIS) for lymphoedema assessment, expanding reimbursement to over 314 million covered lives. This development marks a significant milestone in providing broader access to early detection and monitoring of lymphoedema, enhancing patient care and potentially reducing long-term complications. The expanded insurance coverage is expected to boost the commercial viability of ImpediMed’s SOZO platform, facilitating its adoption and supporting the company’s mission to improve health outcomes for cancer patients at risk of lymphoedema.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the healthcare industry, specializing in digital health solutions. The company is known for its SOZO Digital Health Platform, which utilizes bioimpedance spectroscopy (BIS) for the assessment and management of lymphoedema, particularly in breast cancer survivors.
Average Trading Volume: 1,709,372
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$73.35M
See more data about IPD stock on TipRanks’ Stock Analysis page.